Literature DB >> 17210794

Effect of elevated serum uric acid on cisplatin-induced acute renal failure.

Carlos A Roncal1, Wei Mu, Byron Croker, Sirirat Reungjui, Xiaosen Ouyang, Isabelle Tabah-Fisch, Richard J Johnson, A Ahsan Ejaz.   

Abstract

Marked hyperuricemia is known to cause acute renal failure via intrarenal crystal deposition. However, recent studies suggest mild hyperuricemia may have vasoactive and proinflammatory effects independent of crystal formation. We therefore tested the hypothesis that mild hyperuricemia might exacerbate renal injury and dysfunction in a model of cisplatin-induced acute renal failure in the rat. Cisplatin was administered to normouricemic and hyperuricemic rats (the latter generated by administering the urate oxidase inhibitor, oxonic acid). Recombinant urate oxidase (rasburicase) was administered in a third group to assess the effect of lowering uric acid on outcomes. Other control groups include normal rats and hyperuricemic rats without cisplatin-induced injury. Cisplatin induced injury of the pars recta (S3) segment of the proximal tubule in association with a mild monocyte infiltration. Hyperuricemic rats showed significantly greater tubular injury and proliferation with significantly greater macrophage infiltration and increased expression of monocyte chemoattractant protein-1. However, renal function was not different between normouricemic and hyperuricemic rats with cisplatin injury. Treatment with rasburicase reversed the inflammatory changes and lessened tubular injury with an improvement in renal function (relative to the hyperuricemic group). No intrarenal crystals were observed in any groups. These data provide the first experimental evidence that uric acid, at concentrations that do not cause intrarenal crystal formation, may exacerbate renal injury in a model of acute renal failure. The mechanism may relate to a proinflammatory pathway involving chemokine expression with leukocyte infiltration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210794     DOI: 10.1152/ajprenal.00160.2006

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  49 in total

Review 1.  Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal.

Authors:  Tuhina Neogi; Jacob George; Sushma Rekhraj; Allan D Struthers; Hyon Choi; Robert A Terkeltaub
Journal:  Arthritis Rheum       Date:  2012-02

2.  Rasburicase in the treatment of hyperuricemia of newborns.

Authors:  Stefano Ghirardello; Gianluigi Ardissino; Antonio Mastrangelo; Fabio Mosca
Journal:  Pediatr Nephrol       Date:  2010-04-08       Impact factor: 3.714

3.  Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery.

Authors:  A Ahsan Ejaz; Bhagwan Dass; Vijaykumar Lingegowda; Michiko Shimada; Thomas M Beaver; Noel I Ejaz; Amer S Abouhamze; Richard J Johnson
Journal:  Int Urol Nephrol       Date:  2012-05-31       Impact factor: 2.370

Review 4.  Uric acid as a mediator of diabetic nephropathy.

Authors:  Diana I Jalal; David M Maahs; Peter Hovind; Takahiko Nakagawa
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

Review 5.  Systemic inflammation, metabolic syndrome and progressive renal disease.

Authors:  Pietro Cirillo; Yuri Y Sautin; John Kanellis; Duk-Hee Kang; Loreto Gesualdo; Takahiko Nakagawa; Richard J Johnson
Journal:  Nephrol Dial Transplant       Date:  2009-02-10       Impact factor: 5.992

6.  Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study.

Authors:  Iddo Z Ben-Dov; Jeremy D Kark
Journal:  Nephrol Dial Transplant       Date:  2011-01-10       Impact factor: 5.992

Review 7.  Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis.

Authors:  Ye-Fang Zhang; Fan He; Hong-Hui Ding; Wei Dai; Qian Zhang; Hong Luan; Yong-Man Lv; Hong-Bing Zeng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-08-19

Review 8.  Uric acid as a target of therapy in CKD.

Authors:  Diana I Jalal; Michel Chonchol; Wei Chen; Giovanni Targher
Journal:  Am J Kidney Dis       Date:  2012-10-09       Impact factor: 8.860

9.  Urate oxidase knockdown decreases oxidative stress in a murine hepatic cell line.

Authors:  Beth M Cleveland; Stephen S Leonard; Hillar Klandorf; Kenneth P Blemings
Journal:  Oxid Med Cell Longev       Date:  2009 Apr-Jun       Impact factor: 6.543

10.  Rasburicase improves hyperuricemia in infants with acute kidney injury.

Authors:  David J Hobbs; Julia M Steinke; Jin Y Chung; Gina-Marie Barletta; Timothy E Bunchman
Journal:  Pediatr Nephrol       Date:  2009-11-21       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.